Gri Bio Inc (GRI) Stock Price, Quote & News

Company Profile

GRI Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies that target diseases leading to inflammatory, fibrotic, and autoimmune disorders in the United States. Its lead product candidate is GRI-0621, an oral inhibitor of type 1 Natural Killer T cells, which is in phase IIa clinical trial for the treatment of severe fibrotic lung diseases, such as idiopathic pulmonary fibrosis. The company's portfolio also includes GRI-0803, a no...

Industry: Biotechnology

Sector: Healthcare

Phone: 619 400 1170

Website: www.gribio.com

Address:

2223 Avenida de la Playa, Suite 208, La Jolla, United States

Gamblingisfun Jan. 5 at 1:57 AM

$GRI I’ll load now thanks very much. Hahahaha clown fuck!

0 · Reply

Gamblingisfun Jan. 5 at 1:56 AM

$GRI but it’s down 87% since this post

0 · Reply

Elmaestro11 Jan. 2 at 11:51 PM

$GRI After hours shenanigans I see Just vote no on the proposed Reverse split we need to send a message. We have a gap to fill 🤓

1 · Reply

Mahdinur Jan. 2 at 10:03 PM

$GRI Lol How many times did you go out? Or do you keep going back in?

0 · Reply

elkhro Jan. 2 at 9:53 PM

$GRI

0 · Reply

elkhro Jan. 2 at 9:20 PM

$GRI

0 · Reply

Draindrop Jan. 2 at 9:16 PM

$GRI

0 · Reply

DFWxplorer Jan. 2 at 8:54 PM

$MREO & $GRI Let’s eat!!!

0 · Reply

SingleCellOrganism Jan. 2 at 8:41 PM

$GRI literally tried buying 10 minutes ago but webull didn’t give me my buying power from my previous sale

1 · Reply

thedavidsonny Jan. 2 at 8:41 PM

$GRI 🔥 🔥 🔥 🔥 🔥 Looks like we got a runner!!!

0 · Reply

GRI Bio Announces Closing of $8.0 Million Public Offering

Dec 11, 2025, 9:15 AM EST - 24 days ago

GRI Bio Announces Pricing of $8,000,000 Million Public Offering

Dec 10, 2025, 4:05 PM EST - 25 days ago

GRI Bio Announces Positive Topline Data from its Phase 2a Study in Idiopathic Pulmonary Fibrosis (“IPF”)

Sep 11, 2025, 8:45 AM EDT - 4 months ago

GRI Bio Reports 6-Week Interim Lung Function Data in Ongoing Phase 2a Study in Idiopathic Pulmonary Fibrosis (“IPF”)

Aug 14, 2025, 9:15 AM EDT - 5 months ago

GRI Bio to Present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTech

Jul 31, 2025, 1:50 PM EDT - 5 months ago

GRI Bio CEO, Marc Hertz, Participates in Virtual Investor “What This Means” Segment

Jul 22, 2025, 8:45 AM EDT - 5 months ago

GRI Bio Participates in the Virtual Investor “What's Your Story” Summer Spotlight On-Demand Conference

Jul 1, 2025, 8:45 AM EDT - 6 months ago

GRI Bio Completes Enrollment in Phase 2a Study of GRI-0621 for the Treatment of Idiopathic Pulmonary Fibrosis (“IPF”)

Jun 26, 2025, 8:00 AM EDT - 6 months ago

GRI Bio's GRI-0621 Demonstrates Encouraging Safety Results at Planned Interim 6-Week Analysis in Ongoing Phase 2a Study in Idiopathic Pulmonary Fibrosis (“IPF”)

May 21, 2025, 9:15 AM EDT - 8 months ago

GRI Bio to Participate in the Virtual Investor Closing Bell Series

May 16, 2025, 9:15 AM EDT - 8 months ago

GRI Bio to Present at A.G.P.'s Annual Healthcare Company Showcase

May 15, 2025, 8:35 AM EDT - 8 months ago

GRI Bio Reports First Quarter 2025 Financial Results and Confirms GRI-0621 Phase 2a IPF Trial on Track for 6-Week Interim Data in Q2 2025 and Topline Data in Q3 2025

May 8, 2025, 8:45 AM EDT - 8 months ago

GRI Bio's Interim Biomarker Data Demonstrate Positive Trend Towards Anti-Fibrotic Effect of GRI-0621 in First Twelve Patients of Ongoing Phase 2a Study in Idiopathic Pulmonary Fibrosis (“IPF”)

May 7, 2025, 9:15 AM EDT - 8 months ago

GRI Bio Continues to Drive Enrollment in Ongoing Phase 2a Study of GRI-0621 in Idiopathic Pulmonary Fibrosis (“IPF”)

Apr 16, 2025, 8:35 AM EDT - 9 months ago

GRI Bio Announces Abstract Selected for Poster Discussion Session at the 2025 American Thoracic Society (ATS) International Conference

Apr 2, 2025, 4:05 PM EDT - 9 months ago

GRI Bio Announces Closing of $5.0 Million Public Offering

Apr 1, 2025, 11:15 AM EDT - 9 months ago

GRI Bio Announces Pricing of $5.0 Million Public Offering

Apr 1, 2025, 11:07 AM EDT - 9 months ago

Why Is Nano Cap GRI Bio Stock Skyrocketing On Tuesday?

Mar 31, 2025, 8:00 AM EDT - 9 months ago

GRI Bio Bolsters Intellectual Property Portfolio with Granting of Two Global Patents for Europe and Japan

Mar 18, 2025, 9:05 AM EDT - 10 months ago

GRI Bio Participates in a Virtual Investor CEO Connect Segment

Mar 17, 2025, 8:05 AM EDT - 10 months ago

GRI Bio Reports Full Year 2024 Financial Results and Reiterates Expected Clinical Data Readouts in 2025 for Ongoing Phase 2a Study of GRI-0621 in Idiopathic Pulmonary Fibrosis (“IPF”)

Mar 11, 2025, 8:35 AM EDT - 10 months ago

GRI Bio Regains Compliance with Nasdaq's Minimum Bid Price Rule

Feb 19, 2025, 4:05 PM EST - 11 months ago

GRI Bio Announces Reverse Stock Split

Feb 19, 2025, 9:00 AM EST - 11 months ago

GRI Bio, Inc. Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference

Dec 23, 2024, 9:00 AM EST - 1 year ago

GRI Bio Announces European Patent Office Issued a Decision to Grant Notice for Patent Covering GRI-0803 and Its Library of 500+ Proprietary Compounds

Nov 21, 2024, 8:45 AM EST - 1 year ago

GRI Bio Showcases GRI-0621's Potential to Reduce Inflammation, Type 1 Cytokines and Reduce Hepatic Fibrosis in Idiopathic Pulmonary Fibrosis (IPF)

Nov 14, 2024, 4:20 PM EST - 1 year ago

GRI Bio Reports Third Quarter 2024 Financial Results and Outlines Progress Towards Clinical Data Readout of GRI-0621 in Ongoing Phase 2a Study for Idiopathic Pulmonary Fibrosis

Oct 24, 2024, 8:30 AM EDT - 1 year ago

GRI Bio Raises a Total of $13.9 Million in Gross Proceeds Since the Beginning of 2024

Oct 21, 2024, 5:35 PM EDT - 1 year ago

GRI Bio Announces Exercise of Warrants

Oct 16, 2024, 8:45 AM EDT - 1 year ago

GRI Bio Presents Positive Preclinical Data Demonstrating GRI-0621's Ability to Inhibit Invariant Natural Killer T (iNKT) Cell Activity and Reduce Important Inflammatory and Fibrotic Drivers in Idiopathic Pulmonary Fibrosis (IPF)

Sep 30, 2024, 8:30 AM EDT - 1 year ago

GRI Bio Granted Japan Patent for Proprietary Natural Killer T (NKT) Cell Modulators for Prevention and Treatment of Inflammatory Conditions

Sep 25, 2024, 8:45 AM EDT - 1 year ago

GRI Bio (NASDAQ: GRI) to Participate in a Virtual Investor CEO Connect Segment

Sep 5, 2024, 8:45 AM EDT - 1 year ago

GRI Bio to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Sep 4, 2024, 8:45 AM EDT - 1 year ago

GRI Bio to Present at the 2024 European Respiratory Congress

Aug 14, 2024, 8:05 AM EDT - 1 year ago

GRI Bio Reports Second Quarter 2024 Financial Results and Provides Corporate Update

Jul 15, 2024, 9:05 AM EDT - 1 year ago

GRI Bio (NASDAQ: GRI) to Participate in the Virtual Investor Lunch Break Series

Jul 11, 2024, 9:20 AM EDT - 1 year ago

GRI Bio (NASDAQ: GRI) Participates in Virtual Investor “What This Means” Segment

Jul 8, 2024, 9:05 AM EDT - 1 year ago

GRI Bio Regains Compliance with Nasdaq

Jul 2, 2024, 9:05 AM EDT - 1 year ago

GRI Bio Announces Publication of Positive Preclinical Data from Lead Program GRI-0621 in the American Journal of Respiratory and Critical Care Medicine

Jul 1, 2024, 8:45 AM EDT - 1 year ago

GRI Bio to Present at the 8th Annual IPF Summit

Jun 28, 2024, 4:05 PM EDT - 1 year ago

GRI Bio Announces Closing of $4.0 Million Public Offering

Jun 27, 2024, 9:00 AM EDT - 1 year ago

GRI Bio Announces Korea Patent Granted for Proprietary Natural Killer T (NKT) Cell Modulators

May 22, 2024, 9:15 AM EDT - 1 year ago

GRI Bio (NASDAQ: GRI) Participates in Virtual Investor “What This Means” Segment Highlighting Positive Preclinical Data from Idiopathic Pulmonary Fibrosis (IPF) and Systemic Lupus Erythematosus (SLE) Programs

May 21, 2024, 8:35 AM EDT - 1 year ago

GRI Bio Presents Positive Preclinical Data from Pipeline of NKT Cell Modulators in Development for the Treatment of Systemic Lupus Erythematosus (SLE)

May 20, 2024, 8:45 AM EDT - 1 year ago

GRI Bio Presents Positive Preclinical Data Demonstrating Lead Program GRI-0621 Reduces the Important Inflammatory and Fibrotic Drivers in Idiopathic Pulmonary Fibrosis (IPF)

May 14, 2024, 9:05 AM EDT - 1 year ago

GRI Bio to Present at Alliance Global Partner's 2024 Healthcare Company Showcase

May 13, 2024, 8:00 AM EDT - 1 year ago

GRI Bio Reports First Quarter 2024 Financial Results and Provides Corporate Update

Apr 29, 2024, 8:45 AM EDT - 1 year ago

GRI Bio Announces Abstracts Accepted for Presentation at the 14th International Congress on Autoimmunity

Apr 25, 2024, 9:15 AM EDT - 1 year ago

GRI Bio to Present at LIVE! with Webull Corporate Connect: Virtual Biotech Investment Webinar

Apr 16, 2024, 8:35 AM EDT - 1 year ago

GRI Bio Expands Intellectual Property Protection for Proprietary Natural Killer T (NKT) Cell Modulators with Issuance of Korea Patent

Gamblingisfun Jan. 5 at 1:57 AM

$GRI I’ll load now thanks very much. Hahahaha clown fuck!

0 · Reply

Gamblingisfun Jan. 5 at 1:56 AM

$GRI but it’s down 87% since this post

0 · Reply

Elmaestro11 Jan. 2 at 11:51 PM

$GRI After hours shenanigans I see Just vote no on the proposed Reverse split we need to send a message. We have a gap to fill 🤓

1 · Reply

Mahdinur Jan. 2 at 10:03 PM

$GRI Lol How many times did you go out? Or do you keep going back in?

0 · Reply

elkhro Jan. 2 at 9:53 PM

$GRI

0 · Reply

elkhro Jan. 2 at 9:20 PM

$GRI

0 · Reply

Draindrop Jan. 2 at 9:16 PM

$GRI

0 · Reply

DFWxplorer Jan. 2 at 8:54 PM

$MREO & $GRI Let’s eat!!!

0 · Reply

SingleCellOrganism Jan. 2 at 8:41 PM

$GRI literally tried buying 10 minutes ago but webull didn’t give me my buying power from my previous sale

1 · Reply

thedavidsonny Jan. 2 at 8:41 PM

$GRI 🔥 🔥 🔥 🔥 🔥 Looks like we got a runner!!!

0 · Reply

Wildblitz Jan. 2 at 8:05 PM

$GRI outta this trash- making money elsewhere

2 · Reply

LuckyRing Jan. 2 at 8:03 PM

$GRI Market cap is 1.5 million - they never should of requested more shares. 8 million vanished in a week.

0 · Reply

Stock_King786 Jan. 2 at 7:46 PM

$GRI go past .25, you know you want to

0 · Reply

DFWxplorer Jan. 2 at 6:58 PM

$GRI Looking juicy!

0 · Reply

Mahdinur Jan. 2 at 6:31 PM

$LVRO $GRI What an amazing ride Shouldn't profits go to GRI?

0 · Reply

Mahdinur Jan. 2 at 5:50 PM

$LVRO wow $0.2 to $1.4 $GRI from $2.X to $0.2, soon to wake up.

1 · Reply

Stock_King786 Jan. 2 at 4:34 PM

$GRI need to get past .25 to see some action

0 · Reply

Stock_King786 Jan. 2 at 4:10 PM

$GRI 🥳 let’s gooooo 🚀

0 · Reply

mortimerT Jan. 2 at 3:53 PM

$GRI this is nothing but a stock selling scam. Next move is a R/S, followed by another huge offering. That's what this company does. They have no kind of business otherwise.

0 · Reply

Emeraldgem Jan. 2 at 2:52 PM

$GRI it’s time for GRI to put up or shut up .

0 · Reply

Stock_King786 Jan. 2 at 2:23 PM

$GRI is today the day? 😏 let’s see .30, .35, and .40+++

1 · Reply

Emeraldgem Jan. 2 at 2:14 PM

$GRI load boat for what , they only gonna take the shares back away from you , and leave you with just a few shares with a higher price they thrown on you and then turn around and keep price low for another year just to excite new investors and turn around and do the same to the new investors, just a repeat pattern .

0 · Reply

Market Cap	915,000.00
Revenue (ttm)	0.00
Net Income (ttm)	-8.21M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	2,924,900
Avg Vol	2,054,058
Day's Range	N/A - N/A
Shares Out	3.27M
Stochastic %K	37%
Beta	-1.39
Analysts	Sell
Price Target	$23.00